Skip to main content

Revolution Medicines

Revolution Medicines, Inc. is an American clinical-stage oncology biopharmaceutical company focused on developing targeted therapies for RAS-addicted cancers. The enterprise develops novel small-molecule inhibitors designed to selectively target the active RAS-ON state, which drives tumor growth across various RAS-mutated solid tumors. Its pipeline features clinical candidate compounds such as elinorasib and zoldatrasib targeting pancreatic ductal adenocarcinoma, non-small cell lung cancer, and colorectal cancer. As a development-stage biopharmaceutical company, it currently generates negligible commercial revenue and relies on equity financing and strategic partnerships. Revolution Medicines maintains a specialized research position in precision oncology focused on RAS pathway inhibition. The ultimate end markets for its therapeutic pipeline encompass oncologists and cancer care facilities globally. Corporate headquarters are located in Redwood City, California, United States. Revolution Medicines is listed on the Nasdaq Global Select Market.

43 of the funds FundTelligence covers report a position in Revolution Medicines.

Legal name
Revolution Medicines Inc
Sector
Health Care
Country
United States
Funds holding it
43
Exposure themes
Precision Medicine & Genomics, Precision Oncology, Precision Therapeutics

Funds holding Revolution Medicines

Showing the 8 largest of 43 funds holding it.

Loading...